- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC
Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).
Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non—small cell lung cancer (NSCLC).
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, has had a significant impact on the landscape since its FDA approval, Perez-Soler explains. This agent is able to target the significant number of patients who develop acquired T790M resistance to EGFR-targeted therapies.
Additionally, osimertinib is not associated with some of the toxicities frequently reported with EGFR inhibitors, including rash. Perez-Soler also explains that osimertinib has demonstrated higher levels of efficacy than gefinitib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif). Patient quality of life is also significantly improved on this agent, he says.
<<<